Amendment: SEC Form SC 13G/A filed by Merus N.V.

$MRUS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $MRUS alert in real time by email
SC 13G/A 1 tm2419961d1_sc13ga.htm SC 13G/A

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 

MERUS N.V.

(Name of Issuer)

 

Common Shares, nominal value €0.09 per share

(Title of Class of Securities)

 

N5749R100

(CUSIP Number)

 

June 30, 2024

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

  13G (Amendment No. 1) Page 2 of 5 Pages

         
1.  

NAMES OF REPORTING PERSONS

 

Incyte Corporation

   
2.   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    
¨
(b)    ¨
   
3.   SEC USE ONLY
 
   
4.   CITIZENSHIP OR PLACE OF ORGANIZATION
 
Delaware
   

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
  5.   SOLE VOTING POWER
 
1,008,076
  6.   SHARED VOTING POWER
 
0
  7.   SOLE DISPOSITIVE POWER
 
1,008,076
  8.   SHARED DISPOSITIVE POWER
 
0

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,008,076

   
10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    
¨
   
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

1.5%*

   
12.  

TYPE OF REPORTING PERSON (see instructions)

 

CO

   
   

 

*See footnotes to Item 4 below.

   

 

 

 

 

  13G (Amendment No. 1) Page 3 of 5 Pages

 

Item 1(a) Name of Issuer:
   
  Merus N.V. (“Merus”)
   
Item 1(b) Address of Issuer’s Principal Executive Offices:
   
  Upsalalaan 17, 3584 CT Utrecht, The Netherlands
   
Item 2(a) Name of Person Filing:
   
  Incyte Corporation (“Incyte”)
   
Item 2(b) Address of the Principal Business Office or, if none, Residence:
   
  1801 Augustine Cut-Off, Wilmington, DE 19803
   
Item 2(c) Citizenship:
   
  Delaware
   
Item 2(d) Title of Class of Securities:
   
  common shares, nominal value €0.09 per share (“Common Shares”)
   
Item 2(e) CUSIP Number:
   
  N5749R100
   
Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
   
  Not applicable
   
Item 4. Ownership

 

  (a) Amount beneficially owned:  1,008,076 shares
   
  (b) Percent of class:  1.5%(1)
   
  (c) Number of shares as to which the person has: 
   
  (i) Sole power to vote or to direct the vote:  1,008,076 shares
   
  (ii) Shared power to vote or to direct the vote:  0
   
  (iii) Sole power to dispose or to direct the disposition of:  1,008,076 shares (2)
   
  (iv) Shared power to dispose or to direct the disposition of:  0

 

(1)The ownership percentage of Incyte has been calculated based on a total of 67,370,051 Common Shares outstanding as of May 30, 2024, as disclosed by Merus in its Prospectus Supplement filed pursuant to Rule 424(b)(5) and its Current Report on Form 8-K, both filed with the Securities and Exchange Commission on May 30, 2024.

 

 

 

 

  13G (Amendment No. 1) Page 4 of 5 Pages

 

Item 5.Ownership of Five Percent or Less of a Class.
  
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.
   
Item 6.Ownership of More than Five Percent on Behalf of Another Person.
  
  Not applicable
   
Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
  
  Not applicable
   
Item 8.Identification and Classification of Members of the Group.
  
  Not applicable
   
Item 9.Notice of Dissolution of Group.
  
  Not applicable
   
Item 10.Certification.
  
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

 

 

 

 

  13G (Amendment No. 1) Page 5 of 5 Pages

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: July 24, 2024

 

  INCYTE CORPORATION
     
  By: /s/ Sheila A. Denton
    Sheila A. Denton
    Executive Vice President and
    General Counsel

 

 

 

Get the next $MRUS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MRUS

DatePrice TargetRatingAnalyst
2/13/2025$84.00Overweight
Piper Sandler
2/7/2025$91.00Overweight
Wells Fargo
11/21/2024$73.00Buy
Goldman
10/24/2024$72.00Buy
UBS
3/28/2024$69.00Buy
Truist
3/4/2024$42.00 → $65.00Buy
Needham
11/2/2023$45.00Buy
Canaccord Genuity
8/21/2023Outperform
TD Cowen
More analyst ratings

$MRUS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

    -  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 -  Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 -  Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical data planned for 2H25 -  Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherla

    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Merus to Present at Upcoming Investor Conferences

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: TD Cowen 45th Annual Health Care Conference: Tuesday, March 4 at 9:10 a.m. ET Leerink Partners Global Healthcare Conference: Monday, March 10 at 11:20 a.m. ET The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's

    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to petosemtamab in combination with pembrolizumab for the first-line treatment of adult patients with recurrent or metastatic programmed death-ligand 1 (PD-L1) positive head and neck squamous cell carcinoma (r/m HNSCC) with combined positive score (CPS) ≥ 1. This second BTD designation fo

    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRUS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MRUS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MRUS
SEC Filings

See more

$MRUS
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • December 6, 2024 - FDA Roundup: December 6, 2024

    For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRUS
Leadership Updates

Live Leadership Updates

See more
  • Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development f

    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors. "I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech e

    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr

    $INCY
    $MRUS
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

$MRUS
Financials

Live finance-specific insights

See more
  • Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

    -  Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 -  Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 -  Petosemtamab evaluation in mCRC ongoing in combination with standard chemotherapy in 1L and 2L and monotherapy in 3L+; mCRC initial clinical data planned for 2H25 -  Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into 2028 UTRECHT, The Netherla

    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

    Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data planned for 2025 – Conference Call on Saturday, December 7th at 9:00 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced interim clinical data as of a July 5, 2024 data cutoff from the ongoing phase 1/2 trial of petosemtamab, a Biclonics® tar

    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

    – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference call on Saturday, Dec. 7 at 9:00 a.m. ET to discuss full data set UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract regarding petosemtamab, a Biclonics® targeting EGFR and LGR5, in previously treated (2L+) patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)

    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRUS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more